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Background: Approximately 17.3 million adults in the United States have had a minimum of
one major depressive episode. Comorbidity of depression and pain can affect individuals of any
age, but is more prevalent in the elderly affecting up to 13% of people in the elderly population.
Given that depression and suicidal ideation (SI) pose a considerable burden resulting in enormous
suffering, there is a need to understand the factors of the relationship between chronic pain (CP),
depression, and SI.
Objectives: Our primary objective in this study was to compare suicidality (SI/attempt [SA])
between patients with major depressive disorder (MDD) and CP and a matched control group. The
secondary objective was to compare length of stay, total hospital costs, and discharge disposition
in these populations.
Study Design: The National Inpatient Sample (NIS) dataset developed by the Healthcare Cost
and Utilization Project was used for this study. The NIS is a database of hospital inpatient stays
derived from billing data submitted by hospitals to statewide data organizations across the United
States. We obtained patient records from the NIS dataset for the years 2006 to 2017. All data were
de-identified so Institutional Review Board approval was waived.
Methods: We used mean and standard error to describe continuous data and counts (percentage)
to describe categorical data. Categorical data were compared using Rao-Scott adjusted chi-square
tests and continuous data were compared using Student’s t tests. Matching was performed using
propensity scores in random order with a caliper size of 0.001. To assess predictors associated with
suicidality, logistic regression analysis was performed.
Results: A total of 393,481 patients having MDD with CP (MDD+CP) were included in the analysis.
The mean age was 49.4 years, and 54.9% of patients were women. Overall, rate of composite
outcome of SI/SA was more prevalent in MDD+CP group (51% vs 41%, P < 0.001). Rate of SI was
48% vs 39% (P < 0.001) in the MDD+CP and MDD without CP (MDD-CP) groups, respectively.
MDD+CP was one of the strongest predictors of suicidality, responsible for 48% more risk of SI/SA
compared to MDD-CP group. In comparison to non-Whites, the rate of suicidality was 7.5% less in
White population. Alcohol abuse and substance abuse were associated with 16% and 7% greater
risk of SI/SA, respectively. For women, the odds of having SI/SA was 1.20 greater compared to men.
Limitations: No information was available on the causal relationship between MDD+CP disorder
and SI/SA. Retrospective studies are susceptible to recognition, reporting, and coding bias. There
is no information available on medications use or the duration and severity of CP and bipolar
disorder, which can all be confounding factors.
Conclusions: Psychiatrists and other physicians must be cognizant of the presence of CP and the
risk of suicide, especially when patients present with depressive symptoms. The treatment plan for
this patient population should include routine screening for pain symptoms and risk assessment
for SI.
Key words: Chronic pain, suicidality, suicide, major depressive disorder, opioid use disorder, self
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iagnostic and Statistical Manual of Mental
Disorders, Fifth Edition
categorizes
depressive disorders according to duration,
timing, and presumed etiology. The symptoms of
depressive disorders consist of low mood, diminished
interest, anhedonia, weight change, sleep disruption,
psychomotor
agitation,
fatigue,
feelings
of
worthlessness or guilt, low concentration, and suicidal
ideation (SI), which should last for at minimum of 2
weeks. Such symptoms cause significant distress and
impairment in social and occupational functioning (1).
Approximately 17.3 million adults in the United States
have had a minimum of one major depressive episode.
The prevalence of major depressive episodes is higher
among women (10.5%) compared to men (6.2%) (2).
Depression is a well-known risk factor for chronic pain
(CP) (3).
Comorbidity of depression and pain can affect individuals of any age, but is more prevalent in the elderly
affecting up to 13% of people in the elderly population
(3). High rates of depression among patients with CP
and co-occurring other psychopathology have important treatment implications (4-5). According to a study
in a Canadian population, the prevalence of depression
is 3 times greater in those with chronic back pain than
without CP (6). Overall, patients with CP have a 30% to
40% prevalence of major depression (7).
Suicide and self-harm are also common symptoms
that present with major depressive disorder (MDD).
Data from 2020 suggested more than 45,900 Americans
died by suicide, indicating a rise in suicide attempts
(SAs) and overall deaths (8,9). In one study (10) performed in outpatient hospitals in China, the prevalence
of MDD and one-month prevalence of suicidality were
3.7% and 2.3%, respectively.
Pain tolerance is decreased in major depression,
and somatic preoccupation can be a prominent symptom, especially in older people. Of note, more than
half of the patients presenting with major depression
in primary care report some pain (11). In many cases,
diagnosis is delayed, especially when the diagnosis of
depression is imprecise. Another proposed mechanism
for the relationship is that CP represents a subtype of
depression (12). This is supported by studies (13-15)
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showing that serotonergic and noradrenergic neurotransmitters are involved in both conditions, and
treatments effective for depression are often effective for pain (e.g., opioids, ketamine, antidepressants,
electroconvulsive therapy). However, there is little
clinical evidence to support this notion. Based on the
above-mentioned risk factors, it is not surprising that
MDD is associated with a significantly elevated risk
of early death (13). This is not solely because people
with MDD have an elevated suicide risk (14-15), but
because depression is associated with an elevated risk
of onset, persistence, and severity of a wide range of
physical and mental disorders. Despite advances in the
treatment among patients with depression, suicide
risk is still high. Hence, it is important to target other
factors, such as pain condition, which are not routinely
addressed during the assessment (29).
Given that depression and CP disorders (CPDs) are
interrelated, there is a need to understand the factors
the of the relationship between CP, depression, and SI.
Our primary objective was to compare suicidality (SI/
SA) between patients with MDD and CP and a matched
control group. The secondary objective was to compare
length of stay, total hospital costs, and discharge disposition in these populations.

Methods
The National Inpatient Sample (NIS) dataset (16)
developed by the Healthcare Cost and Utilization
Project was used for this study. The NIS is a database
of hospital inpatient stays derived from billing data
submitted by hospitals to statewide data organizations
across the United States. These inpatient data include
clinical and resource use information typically available
from discharge summaries. The NIS dataset contains
more than 7 million hospital stays each year. There is a
discharge-level weight applied to each record to create
national estimates of inpatient hospitalization. Each
record contains information on age, gender, race, comorbidities, hospital diagnosis, hospitalization charges,
length of stay, hospital location, primary insurance,
admission month, admission day of the week, and
discharge disposition. In the dataset, all diagnoses are
stored in the dataset based on International Classification of Diseases, Ninth Revision, Clinical Modification/
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Procedure Coding System (ICD-9-CM), and International Classification of Diseases, Clinical Modification,
Procedure Coding System (ICD-10-CM/PCS).
We obtained patient records from the NIS dataset
for the years 2006 to 2017. All data were de-identified
so Institutional Review Board approval was waived.
For data collection, we obtained our study cohort
by performing a query for all the adult patients (age
≥ 18), with MDD as a primary indication of admission
and comorbid CPDs (MDD+CP group). We selected
MDD patients by using ICD-9 codes “29620-29626,
29630-29636” and ICD-10 codes “F320-F325, F329-F333,
F3340-F3342, F339” (Supplemental Table 1). For CPDs,
we used ICD-9 codes “33821, 33822, 33828, 33829,
3384” and ICD-10 codes “G8921, G8922, G8928, G8929,
G894” (Supplemental Table 1). For the comparison control group, we selected patients with primary diagnosis
of MDD without comorbid CPDs (MDD-CP group). To
reduce the imbalance between the groups, we matched
the control group based on age, gender, and primary
diagnosis. In addition, we collected data on race, SI/SA,
substance and alcohol abuse, opioid use disorders, and
hypothyroidism (Table 1).

Statistical Analysis
We used mean and standard error (SE) to describe
continuous data and counts (percentage) to describe
categorical data. Categorical data were compared using Rao-Scott adjusted chi-square tests and continuous
data were compared using Student’s t tests. To control
for potential imbalance between groups, we performed 1:1 matching by age, gender, and primary diagnosis code. Matching was performed using propensity
scores in random order with a caliper size of 0.001. To
assess predictors associated with suicidality, logistic
regression analysis was performed. In the multivariate
analysis age, gender, race, drug abuse, alcohol abuse,
and MDD+CP were included (Table 2). Variance inflation factors were used to detect collinearity. Since 15%
of race data were missing, we analyzed it as a separate
category. Odds ratios (OR) and 95% confidence intervals (CI) were used to present the results of logistic
regression analysis. All calculations were performed by
complex survey data analysis techniques using appropriate strata, cluster, and weight variables provided in
the NIS dataset. The statistical analysis was performed
using SAS software version 9.2 (SAS Institute Inc., Cary,
NC) and SPSS version 26.0 software for Windows (IBM
Corporation, Armonk, NY). All tests were 2-sided, with
a P value < 0.05 considered statistically significant.
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Table 1. Baseline patient and hospital characteristics of study
population.

MDD without
CPD
(n = 390,967)

MDD with
CPD
(n = 393,481)

P value

49.2 (0.10%)

49.4 (0.10%)

0.06

Men

177,866 (45.5%)

177,269 (45.1%)

0.13

Women

213,101 (54.5%)

216,212 (54.9%)

White

254,524 (74.9%)

285,252 (82%)

Black

43,699 (12.9%)

32,093 (9.2%)

Hispanic

26,561 (7.8%)

20,401 (5.9%)

3,308 (1%)

2,133 (0.6%)

Native
American

2,111 (0.6%)

2,342 (0.7%)

Other/
Unknown

9,430 (2.8%)

5,804 (1.7%)

Psychotic
Disorders

13,482 (3.4%)

12,715 (3.2%)

0.03

Anxiety
Disorders

143,972 (36.8%)

184,010 (46.8%)

< 0.001

32,693 (8.4%)

79,441 (20.2%)

< 0.001

Alcohol Abuse

107,785 (27.6%)

89,338 (22.7%)

< 0.001

Substance
Abuse

128,989 (33.0%)

180,141 (45.8%)

< 0.001

38,868 (9.9%)

44,266 (11.2%)

< 0.001

Patient Level Characteristics
Age
Mean, SE
Gender

Race

Asian or Pacific
Islander

< 0.001

Comorbidities

Opioid Use
Disorders

Hypothyroidism
Primary Payer

< 0.001

Medicare/
Medicaid

202,313 (51.7%)

244,028 (62%)

Self-pay/Other

59,233 (15.2%)

51,157 (13%)

Private
Insurance

129,421 (33.1%)

98,297 (25%)

Hospital Region

< 0.001

Northeast

85,298 (21.8%)

58,612 (14.9%)

Midwest

113,426 (29%)

108,316 (27.5%)

South

146,462 (37.5%)

170,024 (43.2%)

West

45,781 (11.7%)

56,529 (14.4%)

Routine

343,155 (87.8%)

345,073 (87.7%)

Other Health
Care Facility

42,553 (10.9%)

42,758 (10.9%)

Disposition

0.25
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Table 1 (cont.). Baseline patient and hospital characteristics of
study population.-

Against Medical
Advice
Died

MDD without
CPD
(n = 390,967)

MDD with
CPD
(n = 393,481)

5,107 (1.3%)

5,547 (1.4%)

152 (0%)

P value

103 (0%)

Length of
Hospital Stay,
Days

6.67 (0.05%)

6.70 (0.05%)

0.49

Total Cost, $

17,778 (206)

18,852 (216)

< 0.001

*15% of the race data were missing.
Abbreviations: MDD, major depressive disorder; CPD, chronic pain
disorder; SE, standard error.

Results
Baseline Characteristics
A total of 393,481 patients having MDD+CP were
included in the analysis. The mean age was 49.4 years,
and 54.9% of patients were women. In the MDD-CP
control group (n = 390,067), the mean age was 49.2,
and 54.5% patients were women (Table 1). To avoid the
imbalance between the groups, we matched 2 groups
for age, gender, and primary diagnosis category. In
the matched cohort 393,481 patients were included in
MDD+CP group and 390,967 patients were included in
MDD-CP group.
Baseline characteristics are shown in Table 1.
Eighty-two percent of patients were White in the
MDD+CP group and 74.9% of patients were White in
the MDD-CP group. There were higher proportions of
Hispanics and Blacks in the MDD-CP group. Opioid use
disorders were more common in the MDD+CP group
(20.2% vs 8.4%, P < 0.001) as were anxiety disorders
were more common in the MDD+CP group (46.8% vs
36.8%, P < 0.001). In the MDD-CP group, alcohol abuse
was more prevalent (27.6% vs 22.7%, P < 0.001). Hypothyroidism and d substance abuse were more prevalent
in the MDD+CP group.
Among hospital characteristics, the majority of the
MDD+CP patients had Medicare/Medicaid as their primary payer, when compared to MDD+CP more patients in
the MDD-CP group carried private insurance. Regionally,
MDD+CP was more common in Southern and Midwestern parts of the United States. There were no significant
differences in discharge disposition or length of stay
between groups. However, the total cost of hospitalization was higher in MDD+CP group ($18,852 vs $17,778,
P < 0.001).
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Table 2. Multivariate logistic regression analysis for factors
associated with suicidality.

Variables

Multivariate Analysis
OR (95% CI)

P value

Age, per 5 years increase

0.93 (0.92-0.93)

< 0.001

Women

1.20 (1.18-1.23)

< 0.001

White Race

0.92 (0.88-0.97)

< 0.001

Alcohol Abuse

1.16 (1.13-1.19)

0.003

Drug Abuse

1.07 (1.04-1.10)

< 0.001

MDD+CPD

1.475 (1.424-1.528)

< 0.001

Abbreviations: OR, odds ratio; CI, 95% confidence interval; MDD,
major depressive disorder; CPD, chronic pain disorder.

Predictor of Suicide and Rate of Suicidality
Overall, rate of composite outcome of SI/SA was
more prevalent in the MDD+CP group (51% vs 41%, P
< 0.001) (Fig. 1). Rate of SI was 48% vs 39% (P < 0.001)
in the MDD+CP and MDD-CP groups, respectively. There
was no difference in the SA rate between the groups
(3.8% vs 3.7 %, P = 0.86). In the logistic regression analysis, age, women, White race, alcohol abuse, drug abuse,
and MDD+CP were included as predictors and SI/SA as
an outcome (Table 2). MDD+CP was one of the strongest
predictors of suicidality, responsible for 48% more risk
of SI/SA compared to the MDD-CP group. Each 5-year
increase in age was associated with 7% less risk of SI/SA.
In comparison to non-Whites, the rate of suicidality was
7.5% less in White people. Alcohol abuse and substance
abuse were associated with 16% and 7% greater risk of
SI/SA, respectively. For women, the odds of having SI/SA
was 1.20 greater compared to men.

Discussion
MDD and CP are frequently co-prevalent, and the
2 disorders share demographic, clinical, and neurobiological similarities (17). Understanding the relationship
between these factors and their shared pathophysiology
can aid health care providers in identifying people who
are suffering from CP and are at risk of suicide, as well
as implementing individualized, integrated programs to
treat them (18). To our knowledge, this study is first to
investigate the risk of suicidality in patients with MDD
having comorbid CPD using a large NIS dataset. We
compared the MDD+CP and MDD-CP groups. In baseline
characteristics, the majority of patients were White race
in both groups, with Hispanics and Blacks being more
prevalent in the MDD-CP group. The MDD+CP group had
higher rates of opioid use and anxiety disorders, while the
MDD-CP group had higher rates of alcohol misuse. Medical comorbidities, such as hypothyroidism and substance
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Fig. 1. Rate of SI/SA between the groups.
SI/SA, suicidal ideation/attempt.

abuse, were also more prevalent in the MDD+CP group.
Although there were no significant differences between
the groups in terms of discharge disposition or length of
stay, the MDD+CP group had higher hospitalization costs
(Table 1).
SI was more common in the MDD+CP group than in
the MDD-CP group. There was no difference between
groups when it came to SAs. MDD+CP was one of the
strongest predictors of suicidality in our study. Alcohol
and substance abuse, women, non-White racial background, and younger age were also linked to a higher
incidence of SI/SA.
Nicholl et al (19) in their cross-sectional study,
investigated the prevalence of CP and depression by
ethnic groups and found comorbid CP and depression
were more common in Whites (11.1%) compared to
Asians (7.5%) and Blacks (8.5%). They concluded that
this could be due to cultural differences and language
obstacles, which might make it difficult for minority
ethnic groups to receive quality care. Equally, in our
study population, majority of patients were of the
White race in both groups.
Arnow et al (20) found that patients with comorbid
depression and debilitating CP had considerably lower
health-related quality of life, more severe somatic
symptoms, and a higher prevalence of panic disorder
than those without comorbid depression or CP. CP has
been shown in studies (17,36) to cause (and be exacerbated by) depression, engender hopelessness, facilitate
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a desire for death as an escape, and erode the natural
fear of death.
According to research (21) into the possible factors
responsible for the deterioration of treatment gains in
patients with CP after completion of treatment, depression was more common among individuals who had a
poorer treatment response. Proctor et al (22) found
that the patients’ self-medication attempts to achieve
greater pain relief accounted for most reported reasons for taking more than the prescribed dosage of the
medications. Also, CP patients have high rates of SI and
SA, and access to prescription opioids increases the risk
of suicide death in this patient population (23).
On average, 65% of patients with depression
have one or more pain complaints, while depression is
prevalent in 5% to 85% of patients with CP conditions
(depending on the study environment) (24). According to current evidence, those who suffer from CP are
more likely to suffer from a variety of negative health
outcomes, including suicide. Several predictive factors,
such as pain severity, pain interference, duration of
pain, and specific pain diagnoses (cancer pain vs noncancer pain), were identified, which may increase the
risk of suicidal behavior (25-29). Roughan et al (30) observed that SI was more common in depressed patients
with concurrent CP (OR = 1.49 [CI, 1.38-1.61]) than
those without CP, and a recent attempt at suicide was
linked to persistent pain (OR = 1.88 [CI, 1.14-3.09]). Recent suicidal thoughts and SA were similarly positively
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linked with CP severity (30). In our study, although we
did not evaluate the magnitude of pain, CP by itself
was the strongest predictor of suicidality.
Studies (31-32) have found that taking analgesic
and anxiety medications (such as benzodiazepines) at
the same time, as well as having an alcohol use disorder
or mood illness while on prescription pain medications,
can all enhance the risk of suicide among CP patients.
In our study, we found that abuse of alcohol and illicit
drugs was associated with a 16% and 7% increased risk
of SI/SA, respectively, in the MDD+CP group. As noted
above, psychotropic medications, such as antidepressants and ketamine, as well as nonpharmacological
interventions, such as repetitive transcranial magnetic
stimulation and electroconvulsive therapy, can be beneficial for CP, as well as underlying mood or anxiety
disorders (33-37).
Several limitations should be considered when interpreting these findings. Since this is a cross-sectional
retrospective study, no information was available on
the causal relationship between MDD+CPD and SI/SA.
Retrospective studies, whether they are chart reviews
at academic institutions or hospital claims data (as in

our case), are susceptible to recognition, reporting,
and coding bias. Because our study makes use of a deidentified administrative database, it is susceptible to
coding errors that cannot be individually verified. Due
to the fact that the records in the dataset are discharge
summaries rather than individual patients, it is possible that some patients with multiple admissions were
counted more than once. Last, there is no information
available on medications used or the duration and severity of CP and MDD, which can all be confounding
factors.

Conclusions
Psychiatrists and other physicians must be cognizant of the presence of CP and the risk of suicide,
especially when treating patients present with depressive symptoms. The treatment plan for this patient
population should include routine screening for pain
symptoms and risk assessment for SI. If a patient is
ascertained to be at a high risk of self-injury, an individualized plan of action should be established to mitigate this risk. Contact information for local psychiatric
emergency services should be included in this plan.

Supplemental table available at www.painphysicianjournal.com
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Supplemental Table 1. ICD-9 and ICD-10 used to obtain the study population.

ICD-9 and ICD-10 Codes

MDD

29620

Major depressive affective disorder, single episode, unspecified

29621

Major depressive affective disorder, single episode, mild

29622

Major depressive affective disorder, single episode, moderate

29623

Major depressive affective disorder, single episode, severe, without mention of psychotic behavior

29624

Major depressive affective disorder, single episode, severe, specified as with psychotic behavior

29625

Major depressive affective disorder, single episode, in partial or unspecified remission

29626

Major depressive affective disorder, single episode, in full remission

29630

Major depressive affective disorder, recurrent episode, unspecified

29631

Major depressive affective disorder, recurrent episode, mild

29632

Major depressive affective disorder, recurrent episode, moderate

29633

Major depressive affective disorder, recurrent episode, severe, without mention of psychotic behavior

29634

Major depressive affective disorder, recurrent episode, severe, specified as with psychotic behavior

29635

Major depressive affective disorder, recurrent episode, in partial or unspecified remission

29636

Major depressive affective disorder, recurrent episode, in full remission

F320

Major depressive disorder, single episode, mild

F321

Major depressive disorder, single episode, moderate

F322

Major depressive disorder, single episode, severe without psychotic features

F323

Major depressive disorder, single episode, severe with psychotic features

F324

Major depressive disorder, single episode, in partial remission

F325

Major depressive disorder, single episode, in full remission

F329

Major depressive disorder, single episode, unspecified

F330

Major depressive disorder, recurrent, mild

F331

Major depressive disorder, recurrent, moderate

F332

Major depressive disorder, recurrent, severe without psychotic features

F333

Major depressive disorder, recurrent, severe with psychotic symptoms

F3340

…… unspecified

F3341

Major depressive disorder, recurrent, in partial remission

F3342

Major depressive disorder, recurrent, in full remission

F339 {AU: Move?/ Insert after
“F333” above?}

Major depressive disorder, recurrent, unspecified

ICD-9 and ICD-10 Codes

CP

33821

CP due to trauma

33822

Chronic post-thoracotomy pain

33828

Other chronic postoperative pain

33829

Other CP

3384 {AU: “3384?”/Missing digit?}

CP syndrome

G8921

CP due to trauma

G8922

Chronic post-thoracotomy pain

G8928

Other chronic post-procedural pain

G8929

Other CP

G894 {AU: “G894?”/Missing digit?}

CP syndrome

Abbreviations: ICD-9, International Classification of Diseases, Ninth Revision; ICD-10, International Classification of Diseases, Tenth Revision;
MDD, major depressive disorder; CP, chronic pain.

